Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epcoritamab is a bispecific antibody. It works by simultaneously attaching to a molecule called CD20 on cancerous B-cells and a molecule called CD3 on effector T-cells, which are a type of immune cell. When epcoritamab binds to CD20 and CD3, it brings the two cells together and activates the T-cells to kill the cancerous B-cells. Epcoritamab may incre

Trial Details

NCT ID
NCT06238648
Phase
PHASE2
Sponsor
Academic and Community Cancer Research United
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Biopsy
  • Biospecimen Collection
  • Computed Tomography
  • Epcoritamab
  • Magnetic Resonance Imaging
  • Patient Observation
Locations (sample)
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • New York, New York, United States|40.71427,-74.00597
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584

Key Eligibility Criteria

  • Men and women \>= 18 years of age
  • Documented histological confirmation of diffuse large b-cell lymphoma not otherwise specified \[DLBCL NOS\], primary mediastinal large b-cell lymph…
  • Patients treated with the commercially available CD19-directed CAR-T products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), or li…
  • Documented measurable disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →